DANISH研究长期随访:ICD在非缺血性收缩性心衰中的疗效
DANISH研究长期随访(中位9.5年)显示,在非缺血性收缩性心衰患者中,ICD植入未显著降低全因死亡率(HR 0.89,95%CI 0.74-1.08,P=0.24)。但在≤70岁患者中,ICD与全因死亡、心血管死亡及心源性猝死风险降低相关。
要点
- ICD未显著改善非缺血性收缩性心衰患者总体生存。
- ≤70岁患者中ICD降低全因死亡(HR 0.78)和心血管死亡(HR 0.75)。
- ≤70岁患者心源性猝死风险显著降低(HR 0.42)。
核心结论
- 在中位9.5年随访中,ICD植入未给非缺血性收缩性心衰患者带来总体生存获益。
- 在≤70岁患者中,ICD植入与全因死亡率、心血管死亡和心源性猝死发生率降低相关。
研究设计与样本
- DANISH研究随机分配556例患者接受ICD,560例接受常规临床护理,随访至2016年6月30日。
- 本长期随访研究将患者随访延长至2020年5月18日。
- 分析涵盖总体人群及按年龄(≤70岁和>70岁)分层。
主要发现
- 中位随访9.5年(25-75百分位7.9-10.9年),ICD组208/556例(37%)死亡,对照组226/560例(40%)死亡。
- 总体人群全因死亡:HR 0.89(95%CI 0.74-1.08;P=0.24)。
- ≤70岁患者全因死亡:ICD组117/389例(30%) vs 对照组158/440例(36%),HR 0.78(95%CI 0.61-0.99;P=0.04)。
- >70岁患者全因死亡:ICD组91/167例(54%) vs 对照组68/120例(57%),HR 0.92(95%CI 0.67-1.28;P=0.75)。
- 总体人群心源性猝死:ICD组35/556例(6%) vs 对照组57/560例(10%),HR 0.60(95%CI 0.40-0.92;P=0.02)。
关键数值与推荐
- 总体人群心血管死亡:ICD组147/556例(26%) vs 对照组164/560例(29%),HR 0.87(95%CI 0.70-1.09;P=0.20)。
- ≤70岁患者心血管死亡:ICD组87/389例(22%) vs 对照组122/440例(28%),HR 0.75(95%CI 0.57-0.98;P=0.04)。
- ≤70岁患者心源性猝死:ICD组19/389例(5%) vs 对照组49/440例(11%),HR 0.42(95%CI 0.24-0.71;P=0.0008)。
- >70岁患者心源性猝死:ICD组16/167例(10%) vs 对照组8/120例(7%),HR 1.34(95%CI 0.56-3.19;P=0.39)。
临床怎么用
- 对于非缺血性收缩性心衰患者,选择ICD一级预防时应考虑年龄因素。
- ≤70岁患者可能从ICD植入中获得生存获益,尤其降低心源性猝死风险。
- >70岁患者ICD获益不显著,需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: DANISH (The Danish Study to Assess the Efficacy of Implantable Cardioverter Defibrillators [ICDs] in Patients With Nonischemic Systolic Heart Failure on Mortality) found that primary-prevention ICD implantation was not associated with an overall survival benefit in patients with nonischemic systolic heart failure during a median follow-up of 5.6 years, although there was a beneficial effect on all-cause mortality in patients ≤70 years. This study presents an additional 4 years of follow-up data from DANISH. METHODS: In DANISH, 556 patients with nonischemic systolic heart failure were randomized to receive an ICD and 560 to receive usual clinical care and followed until June 30, 2016. In this long-term follow-up study, patients were followed until May 18, 2020. Analyses were conducted for the overall population and according to age (≤70 and >70 years). RESULTS: During a median follow-up of 9.5 years (25th-75th percentile, 7.9-10.9 years), 208/556 patients (37%) in the ICD group and 226/560 patients (40%) in the control group died. Compared with the control group, the ICD group did not have significantly lower all-cause mortality (hazard ratio [HR] 0.89, [95% CI, 0.74-1.08]; P = 0.24). In patients ≤70 years (n = 829), all-cause mortality was lower in the ICD group than the control group (117/389 [30%] versus 158/440 [36%]; HR, 0.78 [95% CI, 0.61-0.99]; P = 0.04), whereas in patients >70 years (n = 287), all-cause mortality was not significantly different between the ICD and control group (91/167 [54%] versus 68/120 [57%]; HR, 0.92 [95% CI, 0.67-1.28]; P = 0.75). Cardiovascular death showed similar trends (overall, 147/556 [26%] versus 164/560 [29%]; HR, 0.87 [95% CI, 0.70-1.09]; P = 0.20; ≤70 years, 87/389 [22%] versus 122/440 [28%]; HR, 0.75 [95% CI, 0.57-0.98]; P = 0.04; >70 years, 60/167 [36%] versus 42/120 [35%]; HR, 0.97 [95% CI, 0.65-1.45]; P = 0.91). The ICD group had a significantly lower incidence of sudden cardiovascular death in the overall population (35/556 [6%] versus 57/560 [10%]; HR, 0.60 [95% CI, 0.40-0.92]; P = 0.02) and in patients ≤70 years (19/389 [5%] versus 49/440 [11%]; HR, 0.42 [95% CI, 0.24-0.71]; P = 0.0008), but not in patients >70 years (16/167 [10%] versus 8/120 [7%]; HR, 1.34 [95% CI, 0.56-3.19]; P = 0.39). CONCLUSIONS: During a median follow-up of 9.5 years, ICD implantation did not provide an overall survival benefit in patients with nonischemic systolic heart failure. In patients ≤70 years, ICD implantation was associated with a lower incidence of all-cause mortality, cardiovascular death, and sudden cardiovascular death. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00542945.
引用
- Yafasova, Butt, Elming, et al. Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality). Circulation. 2021. PMID: 34882430. doi:10.1161/CIRCULATIONAHA.121.056072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。